Findings from the current study show that plasma GFAP levels are increased in cognitively normal older adults with high brain Aβ load, indicating that elevated plasma GFAP may serve as an early blood-based biomarker to identify individuals at risk of AD, prior to the manifestation of clinical symptoms. The gene discussed is GFAP; the disease is Alzheimer disease.